Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and Nimotuzumab Plus Chemoradiation in Resectable Esophageal Squamous Cell Carcinoma
NCT07457528Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab and nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Major Pathological Response at 3 months. Started Mar 2026; status: recruiting.
02
Drugs
serplulimabnimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07457528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457528.